Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Affimed (AFMD) to $11 from $15 and keeps an Overweight rating on the shares. The firm notes updated NSCLC data continues to meet the minimum bar set by Wells’ key opinion leaders, though the company is going after a higher dose for further differentiation. The firm thinks the strategy makes sense but does note the 1-1.5 year delay and uncertainty in source of funding.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFMD:
- Affimed price target lowered to $7 from $10 at H.C. Wainwright
- Affimed’s Promising Clinical Update on NSCLC Treatment
- Affimed’s AFM24/atezolizumab combination shows positive results in NSCLC trial
- Affimed price target lowered to $15 from $20 at Wells Fargo
- Affimed reports ‘promising’ Phase 1 efficacy, safety data for AFM28